AU2019351530B2 - MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof - Google Patents

MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof Download PDF

Info

Publication number
AU2019351530B2
AU2019351530B2 AU2019351530A AU2019351530A AU2019351530B2 AU 2019351530 B2 AU2019351530 B2 AU 2019351530B2 AU 2019351530 A AU2019351530 A AU 2019351530A AU 2019351530 A AU2019351530 A AU 2019351530A AU 2019351530 B2 AU2019351530 B2 AU 2019351530B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
cancer
compound
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019351530A
Other languages
English (en)
Other versions
AU2019351530A1 (en
Inventor
Rongzhen JIANG
Zhe Wang
Zhihong Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Longwood Biopharmaceuticals Co Ltd
Original Assignee
Shanghai Longwood Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Longwood Biopharmaceuticals Co Ltd filed Critical Shanghai Longwood Biopharmaceuticals Co Ltd
Publication of AU2019351530A1 publication Critical patent/AU2019351530A1/en
Application granted granted Critical
Publication of AU2019351530B2 publication Critical patent/AU2019351530B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019351530A 2018-09-30 2019-09-30 MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof Active AU2019351530B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811160163.0A CN110963958B (zh) 2018-09-30 2018-09-30 一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN201811160163.0 2018-09-30
PCT/CN2019/109428 WO2020064004A1 (zh) 2018-09-30 2019-09-30 一种mdm2抑制剂，及其制备方法、药物组合物和应用

Publications (2)

Publication Number Publication Date
AU2019351530A1 AU2019351530A1 (en) 2021-05-27
AU2019351530B2 true AU2019351530B2 (en) 2022-11-17

Family

ID=69949744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019351530A Active AU2019351530B2 (en) 2018-09-30 2019-09-30 MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof

Country Status (8)

Country Link
US (1) US11299460B2 (https=)
EP (1) EP3858812B1 (https=)
JP (1) JP7338896B2 (https=)
KR (1) KR102610545B1 (https=)
CN (2) CN110963958B (https=)
AU (1) AU2019351530B2 (https=)
ES (1) ES3013859T3 (https=)
WO (1) WO2020064004A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853731B (zh) * 2021-02-04 2026-02-06 上海长森药业有限公司 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用
WO2023089375A1 (en) * 2021-11-22 2023-05-25 Ligature Therapeutics Pte, Ltd. Therapeutic compounds and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180296A (zh) * 2010-06-04 2013-06-26 安姆根有限公司 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376425B2 (en) * 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) * 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CN105358530A (zh) * 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
BR112016010564A2 (pt) * 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808728QA (en) * 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
WO2018092020A1 (en) * 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180296A (zh) * 2010-06-04 2013-06-26 安姆根有限公司 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物

Also Published As

Publication number Publication date
AU2019351530A1 (en) 2021-05-27
EP3858812A1 (en) 2021-08-04
US11299460B2 (en) 2022-04-12
WO2020064004A1 (zh) 2020-04-02
EP3858812A4 (en) 2022-07-06
EP3858812C0 (en) 2024-12-18
CN110963958B (zh) 2025-10-10
US20220002248A1 (en) 2022-01-06
JP2022502448A (ja) 2022-01-11
CN112867708B (zh) 2023-05-12
CN112867708A (zh) 2021-05-28
KR102610545B1 (ko) 2023-12-05
JP7338896B2 (ja) 2023-09-05
ES3013859T3 (en) 2025-04-15
EP3858812B1 (en) 2024-12-18
KR20210093870A (ko) 2021-07-28
CN110963958A (zh) 2020-04-07

Similar Documents

Publication Publication Date Title
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
AU2020213376B2 (en) Compounds and methods for the targeted degradation of the androgen receptor
AU2025200658A1 (en) Compounds, compositions and methods
JP5612661B2 (ja) Ｃ型肝炎ウイルス阻害剤
CA2828478C (en) Serine/threonine kinase inhibitors
ES2386590T3 (es) Inhibidores del virus de la hepatitis C
JP5619289B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN106687446B (zh) 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
TW201100401A (en) Hepatitis C virus inhibitors
US11236086B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
RS60468B1 (sr) Nova jedinjenja
TW202024063A (zh) 一種高活性sting蛋白激動劑化合物
AU2020405536B2 (en) Benzimidazole derivatives
CN116783183B (zh) 用于治疗贫血和癌症的vhl抑制剂
AU2019351530B2 (en) MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN114853731B (zh) 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用
AU2020421654A1 (en) RORγt inhibitor, preparation method thereof and use thereof
HK40043315B (en) Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
WO2025024288A1 (en) Heterocyclic pad4 inhibitors
TW202430501A (zh) 醯基磺胺化合物作為多瘤病毒的抑制劑
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead
HK40043315A (en) Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
OA20759A (en) Benzimidazole derivatives.
HK1237783A1 (en) 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)